Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:46:39 EDT Tue 20 May 2025
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Q:BCLI
- BRAINSTROM CELL THERAPEUTICS -
https://www.brainstorm-cell.com
11:46:39 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
BCLI
- Q
0.3
1.28
·
1.29
1.2
1.28
-0.08
-5.9
1,515.8
1,687
2,441
1.28
1.31
1.13
10.0485 0.7233
11:27:58
May 19
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Up
-- UPC Restricted:
No
Financial Status:
Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - Last 10 of 2441
More trades...
Time ET
Ex
Price
Change
Volume
11:28:07
Q
1.2801
-0.0799
59
11:27:58
Q
1.285
-0.075
400
11:27:58
Q
1.28
-0.08
120
11:27:56
Q
1.29
-0.07
500
11:27:52
Q
1.2809
-0.0791
9
11:27:48
Q
1.29
-0.07
2,500
11:27:45
Q
1.28
-0.08
52
11:27:27
Q
1.29
-0.07
200
11:27:06
Q
1.29
-0.07
100
11:26:59
Q
1.2892
-0.0708
1
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2025-05-19 07:00
U:BCLI
News Release
200
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn(TM) for ALS
2025-05-15 16:05
U:BCLI
News Release
200
BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
2025-05-15 07:30
U:BCLI
News Release
200
BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19
2025-05-07 06:30
U:BCLI
News Release
200
BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025
2025-05-06 07:00
U:BCLI
News Release
200
BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit
2025-04-29 06:30
U:BCLI
News Release
200
BrainStorm's NurOwn(TM) Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting
2025-04-10 07:30
U:BCLI
News Release
200
BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn(TM) in ALS
2025-03-31 07:00
U:BCLI
News Release
200
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
2025-03-26 08:15
U:BCLI
News Release
200
BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
2025-03-24 07:00
U:BCLI
News Release
200
BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update
2024-12-30 08:00
U:BCLI
News Release
200
BrainStorm Issues 2024 Letter to Shareholders
2024-12-09 07:00
U:BCLI
News Release
200
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update
2024-12-03 07:00
U:BCLI
News Release
200
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
2024-12-02 07:00
U:BCLI
News Release
200
BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024
2024-11-14 16:30
U:BCLI
News Release
200
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
2024-11-11 06:00
U:BCLI
News Release
200
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn(TM) Phase 3b Trial Manufacturing
2024-10-30 06:00
U:BCLI
News Release
200
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
2024-10-28 06:00
U:BCLI
News Release
200
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn(TM) Expanded Access Program at 2024 Annual NEALS Meeting
2024-10-07 07:00
U:BCLI
News Release
200
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn(TM) Trial at the 2024 Maxim Healthcare Virtual Summit
2024-09-24 06:00
U:BCLI
News Release
200
BrainStorm Cell Therapeutics Announces Presentations on NurOwn(TM) at 2024 Annual NEALS Meeting